3/ In regards to strictly the personal benefit of protection, most Americans would agree that the decision to get the COVID-19 vaccine should be a personal choice.
The debate becomes murkier though when assessing the risk of the unvaccinated infecting those who are vaccinated.
4/ Again, it is unknown if the vaccine decreases SARS-CoV-2 transmission.
Hypothetical #1: If the vaccine has little to no effect in decreasing transmission, then the argument that vaccine mandates are necessary to protect others is invalidated.
Result: No vaccine mandates.
5/ Hypothetical #2: If the vaccine decreases number of symptomatic COVID-19 cases, it is certainly possible that it decreases transmission of SARS-CoV-2 (even with some asymptomatic spread among the vaccinated).
Result: Debate on vaccine mandates continues.
6/ Let's explore Hypothetical #2 assuming 100 million Americans get vaccinated.
- At 95% efficacy, 5 million vaccinated Americans are still susceptible to COVID-19
- At an IFR of 0.75%, ~40k vaccinated persons may die from COVID-19
This is on par w/ annual deaths from the flu.
7/ NOTE: The above number is under trial conditions and may vary in the real world (e.g. changes in disease prevalence could alter vaccine effectiveness).
Through increasing herd immunity (natural & vaccinations), COVID-19 prevalence may decrease—resulting in even fewer deaths.
8/ Are 40k deaths sufficient to eliminate personal choice on vaccinations through mandates?
Let's compare to the seasonal flu.
Over the past 5 years, flu vaccine effectiveness varies from 19%-48% with 12k to 40k deaths annually in those who got the jab.
9/ The projected 40k COVID-19 deaths in vaccinated persons is within the range of flu deaths among the vaccinated (12k to 40k).
The flu vaccine has never been mandated in the general population or required for air-travel with the exception of specific occupations.
10/ Safety profile differences:
The flu vaccine has been studied and tested for decades with a fairly well identified safety profile.
The COVID-19 vaccine, on the other hand, is an entirely novel mRNA vaccine developed and tested over mere months.
11/ In conclusion, assuming 95% efficacy at preventing COVID-19 and even with decreased transmission, it would be unprecedented on multiple levels to broadly mandate this vaccine.
Vaccination should continue to be an informed decision between a patient and their doctor.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/ There's an unusual pattern for voter turnout in Red, Blue & Swing states.
Changes in voter turnout from 2016 to 2020 has been largely attributed to increases in mail-in votes this election.
Interestingly though, Red & Swing states had the greatest increases in voter turnout.
2/ This is odd because Democrats had a much greater preference for mail-in voting compared to Republicans.
One would expect that the Blue states (more Democrats) would see the greatest increases in voter turnout due to increased mail-in voting--their preferred method after all.
3/ Instead, Blue states actually have the smallest increase (4.8%) in voter turnout this election.
On the other hand, Red States had a 6.6% increase in voter turnout and Swing states had the largest increase at 8.1%.
1/ An unknown side effect of lengthy lockdowns may be decreased crossover immunity to COVID-19.
Research on SARS-CoV-1 suggests that lack of exposure to the common cold coronaviruses could actually worsen morbidity and mortality in those who do eventually get COVID-19.
2/ Researchers infected mice with a general mouse coronavirus and then 2 days later infected those same mice w/ SARS-CoV-1.
They compared the mortality of these mice vs those infected with SARS-CoV-1 who were not first "primed" w/ a general coronavirus.
1/ Growing research demonstrating importance of protective T-cells against SARS-CoV-2 combined w/ prior research on influenza viruses suggest that nasal mucosa T-cells may explain the rising number of "positive" PCR tests while deaths & hospitalizations remain low.
Here's why.👇
2/ We know a large percentage of the uninfected population already possess T-cells in the blood that recognize SARS-CoV-2.
It seems likely our nasal mucosa also possess these protective T-cells considering airborne spread of common cold coronaviruses.
3/ Substantial research on influenza viruses shows conditioned T-cells in the nasal mucosa is associated with rapid viral clearance and decreased transmission to the lungs upon reinfection.
1/ Hong Kong reports the first confirmed case of SARS-CoV-2 reinfection today.
Although it is only a single case, it supports the theory that T-cell immunity (as opposed to antibodies) may be more important in regards to disease course and transmission.
Here's why.
2/ Case summary:
A 33-year-old confirmed case of COVID-19 from March 2020 (positive PCR test along with fever, headache, cough and sore throat) tests positive in routine screening at the Hong Kong airport in August.
This reinfection occurred 142 days after his first infection.
3/ The patient was completely asymptomatic during the course of the second infection.
He did not have a fever, cough, headache or sore throat during the entire course of the reinfection.
Based on genome sequencing though, it is likely that it is a true second infection.
1/ There is growing evidence that T-cell immunity allows populations to reach herd immunity once only 10-20% are infected with SARS-CoV-2.
This would explain why a highly transmissible virus in densely populated areas peaked at 10-20% infected regardless of lockdowns or masks.
2/ The pervasive misconception is that we have zero immunity against COVID-19. Based on this flawed understanding, epidemiologists projected that herd immunity is not reached until 60-70% are infected.
This is almost certainly wrong.
Of course, the media ignores this research
3/ While antibodies against COVID-19 may only last months, T cell immunity can remain protective for years.
In a study of 23 people who survived SARS in 2003, every single one had memory T cells that recognized the SARS virus 17 years later. (Nature)